The Weekly Dose
Why Psychedelics Don't Make You See Things — They Make You Remember
Welcome to the first Weekly Dose — a weekly roundup of the most interesting things happening in the world of psychedelics. Let’s get to it.
THE UPDATES
💊 A PSILOCYBIN-LIKE DRUG JUST EARNED FDA “BREAKTHROUGH” STATUS FOR POSTPARTUM DEPRESSION
Reunion Neuroscience announced this week that luvesilocin — a synthetic, psilocybin-inspired compound — received FDA Breakthrough Therapy Designation for postpartum depression, based on Phase 2 trial results showing significant improvement from a single dose starting within 24 hours.
What it means if you’re new here: Breakthrough Therapy Designation doesn’t mean a drug is approved — it means the FDA thinks it’s promising enough to review faster and collaborate on more closely. Think of it as the FDA saying “we’re watching this carefully.” Postpartum depression affects roughly 1 in 8 new mothers, and current treatments — antidepressants, therapy — are slow to work and often inadequate. A treatment that could work in a single session would be genuinely new.
🔬 SCIENTISTS FINALLY FIGURED OUT WHY PSYCHEDELICS MAKE YOU HALLUCINATE
Researchers at Ruhr-University Bochum have mapped what actually happens in the brain during a psychedelic experience: psychedelics quiet the brain’s visual input system and cause it to fill the gap with vivid fragments drawn from your own memory.
What it means: You’re not seeing things that aren’t there — you’re seeing things that are deeply, (y)ours. The hallucinations are made from your own history. Beyond explaining the experience itself, this finding helps researchers understand how psychedelics might be designed to treat depression and anxiety more precisely.
🏛️ SOUTH DAKOTA JUST VOTED 58-7 TO LEGALIZE PSILOCYBIN — UPON FDA APPROVAL
The South Dakota House of Representatives passed a bill this week to legalize prescription psilocybin the moment the FDA approves it — an overwhelming 58-7 vote. The bill now moves to the state Senate.
What it means: This kind of “trigger law” is a new strategy in psychedelic policy. Instead of legalizing a substance before federal approval, states are passing laws that would automatically take effect once federal approval comes. It’s both pragmatic and a signal: South Dakota — not exactly a progressive stronghold — just voted nearly unanimously to get ready. The direction of travel is hard to miss.
🔬 A SINGLE DOSE OF DMT REDUCED DEPRESSION IN A CLINICAL TRIAL
Researchers at Imperial College London published Phase 2 results showing that a single dose of DMT — a powerful, fast-acting psychedelic — significantly reduced symptoms in people with major depressive disorder, outperforming placebo.
What it means: DMT is best known as the active ingredient in ayahuasca, the traditional Amazonian plant brew. On its own, it produces an intense psychedelic experience that lasts only 20-30 minutes — much shorter than psilocybin. That brevity makes it potentially useful in clinical settings where time matters. This trial, published in Nature Medicine, adds another psychedelic to a growing list showing real promise for depression.
💊 COMPASS PATHWAYS PSILOCYBIN JUST HAD ITS SECOND POSITIVE PHASE 3 TRIAL
Compass Pathways, the leading clinical-stage psychedelic drug company, reported a second successful Phase 3 trial for its psilocybin treatment for treatment-resistant depression — a milestone that brings it significantly closer to potential FDA approval.
What it means: Treatment-resistant depression is exactly what it sounds like: depression that hasn’t improved after multiple medications and rounds of therapy. It affects tens of millions of people globally, and has very few good treatment options. Two successful Phase 3 trials is the standard threshold required before a company can apply for FDA approval. Compass is now preparing to do exactly that.
UNDER THE MICROSCOPE
You’re not seeing things. You’re remembering them.
For as long as people have talked about psychedelic experiences, the word “hallucination” has done most of the work. It’s the word that ends conversations, the word that makes psychiatrists cautious and parents alarmed. You take something, and you see things that aren’t there. What could possibly be therapeutic about that?
A study published last month from Ruhr-University Bochum suggests the word may have been wrong all along — or at least telling only part of the story.
Researchers used an advanced optical imaging technique to watch brain activity unfold across the surface of mice’s brains in real time as psychedelics took effect. What they saw wasn’t the brain generating new content. It was the brain shutting off its intake. Slow, low-frequency waves spread through the visual cortex, damping down the signals coming in from the eyes. At the same time, those same waves traveled to the retrosplenial cortex — a region associated with accessing stored memories — and activated it.
The brain wasn’t inventing. It was remembering.
Lead researcher Professor Dirk Jancke described the result as “a bit like partial dreaming while awake.” Which is a more precise description than “hallucination” in a meaningful way: when you dream, you’re not confused about reality, you’re temporarily unmoored from it, running on internal signal instead of external.
Consider what that reframe means for therapy. The conditions psychedelics are being studied for — depression, PTSD, end-of-life anxiety — all involve a fractured relationship with memory. Trauma is a memory that won’t stay in the past. Depression is sometimes a story the mind tells itself on repeat. If psychedelics work by briefly shifting the brain toward its own archive, loosening fixed patterns by flooding the system with something other than the present — that’s not magic. That’s mechanism.
“Hallucination” makes psychedelics sound like noise. What this research suggests is that they might be, in some sense, signal.
DOSE OF THE WEEK
Sacred Plants as Guides (Youtube) — Terence McKenna was a philosopher, ethnobotanist, and the closest thing the psychedelic world has to a house prophet. He died in 2000, but his lectures live on YouTube in hours-long recordings that feel like they were filmed in someone's backyard. This one is worth your time.
Stay curious. — DOSED